[go: up one dir, main page]

MX2017006083A - Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma. - Google Patents

Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.

Info

Publication number
MX2017006083A
MX2017006083A MX2017006083A MX2017006083A MX2017006083A MX 2017006083 A MX2017006083 A MX 2017006083A MX 2017006083 A MX2017006083 A MX 2017006083A MX 2017006083 A MX2017006083 A MX 2017006083A MX 2017006083 A MX2017006083 A MX 2017006083A
Authority
MX
Mexico
Prior art keywords
tizoxanide
prodrugs
analogue
salt
compositions
Prior art date
Application number
MX2017006083A
Other languages
English (en)
Inventor
Rossignol Jean-Francois
Stachulski Andrew
Original Assignee
Romark Laboratories Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories Lc filed Critical Romark Laboratories Lc
Publication of MX2017006083A publication Critical patent/MX2017006083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen profármacos de tizoxanida, un análogo o sal de la misma. Los profármacos tienen una porción éster que comprende una porción de aminoácido, e incrementan la biodisponibilidad de la tizoxanida, un análogo o sal de la misma. También se describen composiciones y métodos para el tratamiento de una infección intracelular por protozoarios, una infección vírica o un cáncer.
MX2017006083A 2014-11-11 2015-11-11 Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma. MX2017006083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462078384P 2014-11-11 2014-11-11
PCT/US2015/060084 WO2016077420A1 (en) 2014-11-11 2015-11-11 Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof

Publications (1)

Publication Number Publication Date
MX2017006083A true MX2017006083A (es) 2017-11-08

Family

ID=55954973

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006083A MX2017006083A (es) 2014-11-11 2015-11-11 Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.

Country Status (15)

Country Link
US (3) US10100023B2 (es)
EP (1) EP3217795A4 (es)
JP (1) JP6633092B2 (es)
KR (1) KR20170081228A (es)
CN (1) CN107105660A (es)
AU (1) AU2015346413B2 (es)
BR (1) BR112017009651A2 (es)
CA (1) CA2967333A1 (es)
CO (1) CO2017005038A2 (es)
EA (1) EA201790847A1 (es)
IL (1) IL252153A0 (es)
MX (1) MX2017006083A (es)
TW (1) TW201619142A (es)
WO (1) WO2016077420A1 (es)
ZA (1) ZA201703507B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201619142A (zh) 2014-11-11 2016-06-01 羅馬克實驗室有限公司 利用替唑尼特（ｔｉｚｏｘａｎｉｄｅ）、其類似物或鹽類之前驅藥的組成物及治療方法
SI3436074T1 (sl) 2016-03-31 2020-09-30 Romark Laboratories, L.C. Tiazolidne spojine za zdravljenje virusnih infekcij
HUE060671T2 (hu) 2016-04-11 2023-04-28 Genfit Eljárás fibrotikus betegségek kezelésére
US20170290814A1 (en) * 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
WO2017223491A1 (en) * 2016-06-23 2017-12-28 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
WO2021035114A1 (en) * 2019-08-22 2021-02-25 Board Of Regents Of The University Of Nebraska Prodrugs and formulations thereof
US20230140290A1 (en) * 2020-01-26 2023-05-04 The Board Of Regents Of The University Of Texas Sy Salicylamide derivatives and related methods of making
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
US20230330069A1 (en) 2020-08-24 2023-10-19 Romark Laboratories, L.C. Use of thiazolides against coronaviruses
GB202017724D0 (en) 2020-11-10 2020-12-23 Univ Liverpool Pharmaceutically active compound formulations
CN114044761B (zh) * 2021-02-24 2022-05-17 成都贝诺科成生物科技有限公司 一种新的硝基噻唑衍生物及其应用
CN118317775A (zh) * 2021-09-15 2024-07-09 南京强新生物医药有限公司 治疗冠状病毒感染的新联用药物、药物组合物及其用途
WO2023077711A1 (zh) * 2021-11-03 2023-05-11 南方科技大学 预防前列腺癌的药剂的筛选方法及硝唑尼特在制药中的应用
CN114134195B (zh) * 2021-11-03 2024-06-11 南方科技大学 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
BR9808722A (pt) * 1997-05-07 2000-07-11 Romark Lab Lc Composições farmacêuticas de tizoxanida e nitazoxanida
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US20050171169A1 (en) 2004-02-02 2005-08-04 Rossignol Jean F. Combination chemotherapy for helminth infections
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
EP2047850A3 (en) 2005-04-12 2009-07-29 Romark Laboratories, L.C. Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
EP1976516B9 (en) 2006-01-09 2013-10-30 Romark Laboratories, L.C. Viral hepatitis treatment
WO2009035788A1 (en) * 2007-08-03 2009-03-19 Romark Laboratories L.C. Alkylsulfonyl-substituted thiazolide compounds
PT2395840T (pt) 2009-02-13 2020-07-06 Romark Laboratories Lc Formulações farmacêuticas de libertação controlada de nitazoxanida
AU2010247816B2 (en) 2009-05-12 2015-12-17 Romark Laboratories L.C. Haloalkyl heteroaryl benzamide compounds
JP5932640B2 (ja) 2009-06-26 2016-06-08 ロマーク ラボラトリーズ エル．シー． インフルエンザを治療するための化合物および方法
WO2012040170A2 (en) * 2010-09-20 2012-03-29 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
WO2012058378A1 (en) 2010-10-29 2012-05-03 Romark Laboratories L.C. Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses
MX2013004724A (es) * 2010-11-01 2013-08-29 Romark Lab Lc Compuestos de tiazolida alquilsulfinilo-sustituidos.
WO2012158699A1 (en) 2011-05-16 2012-11-22 Romark Laboratories, L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
CN104277012B (zh) * 2013-07-04 2017-04-05 中国人民解放军军事医学科学院毒物药物研究所 替唑尼特氨基羧酸酯，及其在药学中的应用
TW201619142A (zh) * 2014-11-11 2016-06-01 羅馬克實驗室有限公司 利用替唑尼特（ｔｉｚｏｘａｎｉｄｅ）、其類似物或鹽類之前驅藥的組成物及治療方法

Also Published As

Publication number Publication date
CO2017005038A2 (es) 2017-09-20
IL252153A0 (en) 2017-07-31
BR112017009651A2 (pt) 2017-12-19
JP2017537977A (ja) 2017-12-21
EA201790847A1 (ru) 2017-11-30
EP3217795A4 (en) 2018-08-22
US20190040026A1 (en) 2019-02-07
AU2015346413A1 (en) 2017-05-25
US20190276417A1 (en) 2019-09-12
KR20170081228A (ko) 2017-07-11
ZA201703507B (en) 2019-07-31
EP3217795A1 (en) 2017-09-20
US10358428B2 (en) 2019-07-23
AU2015346413B2 (en) 2019-08-29
US10100023B2 (en) 2018-10-16
JP6633092B2 (ja) 2020-01-22
US20170334868A1 (en) 2017-11-23
CN107105660A (zh) 2017-08-29
WO2016077420A1 (en) 2016-05-19
TW201619142A (zh) 2016-06-01
CA2967333A1 (en) 2016-05-19
US10577337B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
MX2017006083A (es) Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
NZ741354A (en) Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
EP3490987A4 (en) NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION.
GB2541571A (en) Pharmaceutical compositions
IL253243A0 (en) Combined preparations for the treatment of cancer or infection
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
EA030204B8 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX386294B (es) Esteres de oxaborol y sus usos
ZA201807438B (en) Methods of treating ocular conditions
PH12017500602A1 (en) Methods for treating ocular conditions
NZ783808A (en) Crystalline forms of c21h22cl2n4o2
MX2018005872A (es) Profarmacos de acido nucleico.
EP3528629A4 (en) SOIL TREATMENT
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
ZA201708364B (en) Cultivation of crops
EP3479785A4 (en) MEDICAL TREATMENT DEVICE
EP3448377A4 (en) METHODS FOR THE TREATMENT OF AN INFECTION
HK1247584A1 (zh) 結晶c21h22c12n4o2丙二酸酯
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
EP3148538A4 (en) Cenicriviroc for the treatment of hiv-2 infection
FR3021871B1 (fr) Composition a base d'anthostema senegalense utilisee comme medicament contre le sida
EP3618877A4 (en) METHOD OF TREATMENT USING AN AMPHETAMINE PRODRUG
HK40025186A (en) Methods for the treatment of leptomeningeal disease
AU2017904511A0 (en) Plant treatment